{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T11:03:29Z","timestamp":1782817409930,"version":"3.54.5"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,3,8]]},"DOI":"10.7759\/cureus.22978","type":"journal-article","created":{"date-parts":[[2022,3,9]],"date-time":"2022-03-09T06:24:52Z","timestamp":1646807092000},"source":"Crossref","is-referenced-by-count":13,"title":["The Role of Myositis-Specific Autoantibodies in the Dermatomyositis Spectrum"],"prefix":"10.7759","author":[{"given":"Harshita","family":"Marasandra Ramesh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sreeya","family":"Gude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shravya","family":"Venugopal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nikhil Chowdary","family":"Peddi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Sravya","family":"Gude","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sravya","family":"Vuppalapati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1080\/14397595.2018.1467257","article-title":"Current diagnosis and treatment of polymyositis and dermatomyositis","volume":"28","author":"Sasaki H","year":"2018","unstructured":"Sasaki H, Kohsaka H. Current diagnosis and treatment of polymyositis and dermatomyositis. Mod Rheumatol. 2018, 28:913-21. 10.1080\/14397595.2018.1467257","journal-title":"Mod Rheumatol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clindermatol.2018.04.003","article-title":"Dermatomyositis: current concepts","volume":"36","author":"Bogdanov I","year":"2018","unstructured":"Bogdanov I, Kazandjieva J, Darlenski R, Tsankov N. Dermatomyositis: current concepts. Clin Dermatol. 2018, 36:450-8. 10.1016\/j.clindermatol.2018.04.003","journal-title":"Clin Dermatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-019-0871-4","article-title":"Juvenile dermatomyositis-clinical phenotypes","volume":"21","author":"Li D","year":"2019","unstructured":"Li D, Tansley SL. Juvenile dermatomyositis-clinical phenotypes. Curr Rheumatol Rep. 2019, 21:74. 10.1007\/s11926-019-0871-4","journal-title":"Curr Rheumatol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan A","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975, 292:344-7. 10.1056\/NEJM197502132920706","journal-title":"N Engl J Med"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan A","year":"1975","unstructured":"Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975, 292:403-7. 10.1056\/NEJM197502202920807","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg IE","year":"2017","unstructured":"Lundberg IE, Tj\u00e4rnlund A, Bottai M, et al.. 2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups. Ann Rheum Dis. 2017, 76:1955-64. 10.1136\/annrheumdis-2017-211468","journal-title":"Ann Rheum Dis"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.06.1309","article-title":"Dermatomyositis: clinical features and pathogenesis","volume":"82","author":"DeWane ME","year":"2020","unstructured":"DeWane ME, Waldman R, Lu J. Dermatomyositis: clinical features and pathogenesis. J Am Acad Dermatol. 2020, 82:267-81. 10.1016\/j.jaad.2019.06.1309","journal-title":"J Am Acad Dermatol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-011-0166-x","article-title":"Pathogenesis of dermatomyositis: role of cytokines and interferon","volume":"13","author":"Kao L","year":"2011","unstructured":"Kao L, Chung L, Fiorentino DF. Pathogenesis of dermatomyositis: role of cytokines and interferon. Curr Rheumatol Rep. 2011, 13:225-32. 10.1007\/s11926-011-0166-x","journal-title":"Curr Rheumatol Rep"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0029161","article-title":"Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases","volume":"7","author":"Wong D","year":"2012","unstructured":"Wong D, Kea B, Pesich R, et al.. Interferon and biologic signatures in dermatomyositis skin: specificity and heterogeneity across diseases. PLoS One. 2012, 7:e29161. 10.1371\/journal.pone.0029161","journal-title":"PLoS One"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15006","article-title":"Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis","volume":"176","author":"Huard C","year":"2017","unstructured":"Huard C, Gull\u00e0 SV, Bennett DV, Coyle AJ, Vleugels RA, Greenberg SA. Correlation of cutaneous disease activity with type 1 interferon gene signature and interferon \u03b2 in dermatomyositis. Br J Dermatol. 2017, 176:1224-30. 10.1111\/bjd.15006","journal-title":"Br J Dermatol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1038\/gene.2011.61","article-title":"Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis","volume":"13","author":"Greenberg SA","year":"2012","unstructured":"Greenberg SA, Higgs BW, Morehouse C, et al.. Relationship between disease activity and type 1 interferon- and other cytokine-inducible gene expression in blood in dermatomyositis and polymyositis. Genes Immun. 2012, 13:207-13. 10.1038\/gene.2011.61","journal-title":"Genes Immun"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2017.07.021","article-title":"Using multi-omics methods to understand dermatomyositis\/polymyositis","volume":"16","author":"Gao S","year":"2017","unstructured":"Gao S, Luo H, Zhang H, Zuo X, Wang L, Zhu H. Using multi-omics methods to understand dermatomyositis\/polymyositis. Autoimmun Rev. 2017, 16:1044-8. 10.1016\/j.autrev.2017.07.021","journal-title":"Autoimmun Rev"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1089\/dna.2018.4256","article-title":"Discovery of key genes in dermatomyositis based on the gene expression omnibus database","author":"Xie S","year":"2018","unstructured":"Xie S, Luo H, Zhang H, Zhu H, Zuo X, Liu S. Discovery of key genes in dermatomyositis based on the gene expression omnibus database. DNA Cell Biol. 2018, 10.1089\/dna.2018.4256","journal-title":"DNA Cell Biol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-018-0733-5","article-title":"Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies","volume":"20","author":"Wolstencroft PW","year":"2018","unstructured":"Wolstencroft PW, Fiorentino DF. Dermatomyositis clinical and pathological phenotypes associated with myositis-specific autoantibodies. Curr Rheumatol Rep. 2018, 20:28. 10.1007\/s11926-018-0733-5","journal-title":"Curr Rheumatol Rep"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000329","article-title":"Recent advances in dermatomyositis-specific autoantibodies","volume":"28","author":"Fujimoto M","year":"2016","unstructured":"Fujimoto M, Watanabe R, Ishitsuka Y, Okiyama N. Recent advances in dermatomyositis-specific autoantibodies. Curr Opin Rheumatol. 2016, 28:636-44. 10.1097\/BOR.0000000000000329","journal-title":"Curr Opin Rheumatol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2014.12.009","article-title":"Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis","volume":"72","author":"Fiorentino DF","year":"2015","unstructured":"Fiorentino DF, Kuo K, Chung L, Zaba L, Li S, Casciola-Rosen L. Distinctive cutaneous and systemic features associated with antitranscriptional intermediary factor-1\u03b3 antibodies in adults with dermatomyositis. J Am Acad Dermatol. 2015, 72:449-55. 10.1016\/j.jaad.2014.12.009","journal-title":"J Am Acad Dermatol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1684\/ejd.2020.3761","article-title":"The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants","volume":"30","author":"Didona D","year":"2020","unstructured":"Didona D, Juratli HA, Scarsella L, Eming R, Hertl M. The polymorphous spectrum of dermatomyositis: classic features, newly described skin lesions, and rare variants. Eur J Dermatol. 2020, 30:229-42. 10.1684\/ejd.2020.3761","journal-title":"Eur J Dermatol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.21037\/atm-20-5175","article-title":"Dermatomyositis autoantibodies: how can we maximize utility?","volume":"9","author":"Hodgkinson LM","year":"2021","unstructured":"Hodgkinson LM, Wu TT, Fiorentino DF. Dermatomyositis autoantibodies: how can we maximize utility?. Ann Transl Med. 2021, 9:433. 10.21037\/atm-20-5175","journal-title":"Ann Transl Med"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.135.11.1370","article-title":"Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis","volume":"135","author":"Ghali FE","year":"1999","unstructured":"Ghali FE, Stein LD, Fine JD, Burkes EJ, McCauliffe DP. Gingival telangiectases: an underappreciated physical sign of juvenile dermatomyositis. Arch Dermatol. 1999, 135:1370-4. 10.1001\/archderm.135.11.1370","journal-title":"Arch Dermatol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1016\/j.autrev.2014.08.011","article-title":"Four dermatomyositis-specific autoantibodies-anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort","volume":"13","author":"Bodoki L","year":"2014","unstructured":"Bodoki L, Nagy-Vincze M, Griger Z, Betteridge Z, Sz\u00f6ll\u0151si L, Dank\u00f3 K. Four dermatomyositis-specific autoantibodies-anti-TIF1\u03b3, anti-NXP2, anti-SAE and anti-MDA5-in adult and juvenile patients with idiopathic inflammatory myopathies in a Hungarian cohort. Autoimmun Rev. 2014, 13:1211-9. 10.1016\/j.autrev.2014.08.011","journal-title":"Autoimmun Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq153","article-title":"Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis","volume":"49","author":"Hoshino K","year":"2010","unstructured":"Hoshino K, Muro Y, Sugiura K, Tomita Y, Nakashima R, Mimori T. Anti-MDA5 and anti-TIF1-gamma antibodies have clinical significance for patients with dermatomyositis. Rheumatology (Oxford). 2010, 49:1726-33. 10.1093\/rheumatology\/keq153","journal-title":"Rheumatology (Oxford)"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2008.097162","article-title":"Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis","volume":"68","author":"Betteridge ZE","year":"2009","unstructured":"Betteridge ZE, Gunawardena H, Chinoy H, North J, Ollier WE, Cooper RG, McHugh NJ. Clinical and human leucocyte antigen class II haplotype associations of autoantibodies to small ubiquitin-like modifier enzyme, a dermatomyositis-specific autoantigen target, in UK Caucasian adult-onset myositis. Ann Rheum Dis. 2009, 68:1621-5. 10.1136\/ard.2008.097162","journal-title":"Ann Rheum Dis"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-014-0465-0","article-title":"Amyopathic dermatomyositis: definitions, diagnosis, and management","volume":"16","author":"Bailey EE","year":"2014","unstructured":"Bailey EE, Fiorentino DF. Amyopathic dermatomyositis: definitions, diagnosis, and management. Curr Rheumatol Rep. 2014, 16:465. 10.1007\/s11926-014-0465-0","journal-title":"Curr Rheumatol Rep"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s10067-007-0562-9","article-title":"Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study","volume":"26","author":"Ye S","year":"2007","unstructured":"Ye S, Chen XX, Lu XY, et al.. Adult clinically amyopathic dermatomyositis with rapid progressive interstitial lung disease: a retrospective cohort study. Clin Rheumatol. 2007, 26:1647-54. 10.1007\/s10067-007-0562-9","journal-title":"Clin Rheumatol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1007\/s12519-019-00313-8","article-title":"Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment","volume":"16","author":"Wu JQ","year":"2020","unstructured":"Wu JQ, Lu MP, Reed AM. Juvenile dermatomyositis: advances in clinical presentation, myositis-specific antibodies and treatment. World J Pediatr. 2020, 16:31-43. 10.1007\/s12519-019-00313-8","journal-title":"World J Pediatr"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2006.07.008","article-title":"Dermatomyositis as a paraneoplastic syndrome in carcinosarcoma of uterine origin","volume":"18","author":"Chandiramani M","year":"2006","unstructured":"Chandiramani M, Joynson C, Panchal R, Symonds RP, Brown LJ, Morgan B, Decatris M. Dermatomyositis as a paraneoplastic syndrome in carcinosarcoma of uterine origin. Clin Oncol (R Coll Radiol). 2006, 18:641-8. 10.1016\/j.clon.2006.07.008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"ref27","article-title":"How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options","volume":"22","author":"Zerdes I","year":"2017","unstructured":"Zerdes I, Tolia M, Nikolaou M, et al.. How can we effectively address the paraneoplastic dermatomyositis: Diagnosis, risk factors and treatment options. J BUON. 2017, 22:1073-80.","journal-title":"J BUON"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2019.00438","article-title":"Disease specific autoantibodies in idiopathic inflammatory myopathies","volume":"10","author":"Stuhlm\u00fcller B","year":"2019","unstructured":"Stuhlm\u00fcller B, Schneider U, Gonz\u00e1lez-Gonz\u00e1lez JB, Feist E. Disease specific autoantibodies in idiopathic inflammatory myopathies. Front Neurol. 2019, 10:438. 10.3389\/fneur.2019.00438","journal-title":"Front Neurol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15897","article-title":"Paraneoplastic dermatomyositis: relevance of myositis-specific autoantibodies in a small cohort","volume":"34","author":"Maier L","year":"2020","unstructured":"Maier L, Betteridge Z, Udvardi A, Schmid-Simbeck M, Seeber A, Volc-Platzer B. Paraneoplastic dermatomyositis: relevance of myositis-specific autoantibodies in a small cohort. J Eur Acad Dermatol Venereol. 2020, 34:e50-1. 10.1111\/jdv.15897","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1093\/jscr\/rjv075","article-title":"Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy","volume":"2015","author":"Luu X","year":"2015","unstructured":"Luu X, Leonard S, Joseph KA. Dermatomyositis presenting as a paraneoplastic syndrome with resolution of symptoms following surgical management of underlying breast malignancy. J Surg Case Rep. 2015, 2015:10.1093\/jscr\/rjv075","journal-title":"J Surg Case Rep"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2009.03227.x","article-title":"Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology","volume":"34","author":"Madan V","year":"2009","unstructured":"Madan V, Chinoy H, Griffiths CE, Cooper RG. Defining cancer risk in dermatomyositis. Part II. Assessing diagnostic usefulness of myositis serology. Clin Exp Dermatol. 2009, 34:561-5. 10.1111\/j.1365-2230.2009.03227.x","journal-title":"Clin Exp Dermatol"},{"key":"ref32","article-title":"Dermatomyositis and malignancy","volume":"65","author":"Hu T","year":"2019","unstructured":"Hu T, Vinik O. Dermatomyositis and malignancy. Can Fam Physician. 2019, 65:409-11.","journal-title":"Can Fam Physician"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(99)05157-0","article-title":"Dermatomyositis","volume":"1","author":"Callen JP","year":"2000","unstructured":"Callen JP. Dermatomyositis. Lancet. 2000, 1:53-7. 10.1016\/S0140-6736(99)05157-0","journal-title":"Lancet"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.5114\/reum.2015.51510","article-title":"Polymyositis and dermatomyositis as a risk of developing cancer","volume":"53","author":"Jakubaszek M","year":"2015","unstructured":"Jakubaszek M, Kwiatkowska B, Ma\u015bli\u0144ska M. Polymyositis and dermatomyositis as a risk of developing cancer. Reumatologia. 2015, 53:101-5. 10.5114\/reum.2015.51510","journal-title":"Reumatologia"},{"key":"ref35","article-title":"Dermatomyositis associated with breast cancer","volume":"26","author":"Pectasides D","year":"2006","unstructured":"Pectasides D, Koumpou M, Gaglia A, et al.. Dermatomyositis associated with breast cancer. Anticancer Res. 2006, 26:2329-31.","journal-title":"Anticancer Res"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.1016\/j.anorl.2010.10.007","article-title":"Paraneoplastic dermatomyositis accompanying nasopharyngeal carcinoma: diagnosis, treatment and prognosis","volume":"128","author":"Chakroun A","year":"2011","unstructured":"Chakroun A, Guigay J, Lusinchi A, Marandas P, Janot F, Hartl DM. Paraneoplastic dermatomyositis accompanying nasopharyngeal carcinoma: diagnosis, treatment and prognosis. Eur Ann Otorhinolaryngol Head Neck Dis. 2011, 128:127-31. 10.1016\/j.anorl.2010.10.007","journal-title":"Eur Ann Otorhinolaryngol Head Neck Dis"},{"key":"ref37","doi-asserted-by":"publisher","DOI":"10.3747\/co.24.3696","article-title":"Breast cancer and dermatomyositis: a case study and literature review","volume":"24","author":"Hendren E","year":"2017","unstructured":"Hendren E, Vinik O, Faragalla H, Haq R. Breast cancer and dermatomyositis: a case study and literature review. Curr Oncol. 2017, 24:e429-33. 10.3747\/co.24.3696","journal-title":"Curr Oncol"},{"key":"ref38","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-017-1716-7","article-title":"Dermatomyositis and colorectal cancer: a systematic review","volume":"187","author":"Gkegkes ID","year":"2018","unstructured":"Gkegkes ID, Minis EE, Iavazzo C. Dermatomyositis and colorectal cancer: a systematic review. Ir J Med Sci. 2018, 187:615-20. 10.1007\/s11845-017-1716-7","journal-title":"Ir J Med Sci"},{"key":"ref39","doi-asserted-by":"publisher","DOI":"10.1097\/00005792-199405000-00004","article-title":"Ovarian cancer in patients with dermatomyositis","volume":"73","author":"Whitmore SE","year":"1994","unstructured":"Whitmore SE, Rosenshein NB, Provost TT. Ovarian cancer in patients with dermatomyositis. Medicine (Baltimore). 1994, 73:153-60. 10.1097\/00005792-199405000-00004","journal-title":"Medicine (Baltimore)"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.gore.2017.11.009","article-title":"Dermatomyositis - key to diagnosing ovarian cancer, monitoring treatment and detecting recurrent disease: Case report","volume":"23","author":"Field C","year":"2018","unstructured":"Field C, Goff BA. Dermatomyositis - key to diagnosing ovarian cancer, monitoring treatment and detecting recurrent disease: Case report. Gynecol Oncol Rep. 2018, 23:1-3. 10.1016\/j.gore.2017.11.009","journal-title":"Gynecol Oncol Rep"},{"key":"ref41","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-1-68","article-title":"Dermatomyositis and malignancy. A review of the literature","volume":"84","author":"Barnes BE","year":"1976","unstructured":"Barnes BE, Mawr B. Dermatomyositis and malignancy. A review of the literature. Ann Intern Med. 1976, 84:68-76. 10.7326\/0003-4819-84-1-68","journal-title":"Ann Intern Med"},{"key":"ref42","doi-asserted-by":"publisher","DOI":"10.1002\/art.33402","article-title":"Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection","volume":"64","author":"Fiorentino D","year":"2012","unstructured":"Fiorentino D, Casciola-Rosen L. Autoantibodies to transcription intermediary factor 1 in dermatomyositis shed insight into the cancer-myositis connection. Arthritis Rheum. 2012, 64:346-9. 10.1002\/art.33402","journal-title":"Arthritis Rheum"},{"key":"ref43","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/key357","article-title":"The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis","volume":"58","author":"Oldroyd A","year":"2019","unstructured":"Oldroyd A, Sergeant JC, New P, et al.. The temporal relationship between cancer and adult onset anti-transcriptional intermediary factor 1 antibody-positive dermatomyositis. Rheumatology (Oxford). 2019, 58:650-5. 10.1093\/rheumatology\/key357","journal-title":"Rheumatology (Oxford)"},{"key":"ref44","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0120313","article-title":"Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study","volume":"10","author":"Hozumi H","year":"2015","unstructured":"Hozumi H, Enomoto N, Kono M, et al.. Prognostic significance of anti-aminoacyl-tRNA synthetase antibodies in polymyositis\/dermatomyositis-associated interstitial lung disease: a retrospective case control study. PLoS One. 2015, 10:e0120313. 10.1371\/journal.pone.0120313","journal-title":"PLoS One"},{"key":"ref45","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15716","article-title":"Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis","volume":"8","author":"Li L","year":"2017","unstructured":"Li L, Wang Q, Yang F, et al.. Anti-MDA5 antibody as a potential diagnostic and prognostic biomarker in patients with dermatomyositis. Oncotarget. 2017, 8:26552-64. 10.18632\/oncotarget.15716","journal-title":"Oncotarget"},{"key":"ref46","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-020-00502-6","article-title":"Dermatomyositis: an update on diagnosis and treatment","volume":"21","author":"Cobos GA","year":"2020","unstructured":"Cobos GA, Femia A, Vleugels RA. Dermatomyositis: an update on diagnosis and treatment. Am J Clin Dermatol. 2020, 21:339-53. 10.1007\/s40257-020-00502-6","journal-title":"Am J Clin Dermatol"},{"key":"ref47","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2019.1699059","article-title":"Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis","volume":"16","author":"Gono T","year":"2020","unstructured":"Gono T, Kuwana M. Current understanding and recent advances in myositis-specific and -associated autoantibodies detected in patients with dermatomyositis. Expert Rev Clin Immunol. 2020, 16:79-89. 10.1080\/1744666X.2019.1699059","journal-title":"Expert Rev Clin Immunol"},{"key":"ref48","doi-asserted-by":"publisher","DOI":"10.1097\/BOR.0000000000000330","article-title":"Antibodies in juvenile-onset myositis","volume":"28","author":"Tansley SL","year":"2016","unstructured":"Tansley SL. Antibodies in juvenile-onset myositis. Curr Opin Rheumatol. 2016, 28:645-50. 10.1097\/BOR.0000000000000330","journal-title":"Curr Opin Rheumatol"},{"key":"ref49","doi-asserted-by":"publisher","DOI":"10.1007\/s12016-015-8510-y","article-title":"A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy","volume":"52","author":"Satoh M","year":"2017","unstructured":"Satoh M, Tanaka S, Ceribelli A, Calise SJ, Chan EK. A comprehensive overview on myositis-specific antibodies: new and old biomarkers in idiopathic inflammatory myopathy. Clin Rev Allergy Immunol. 2017, 52:1-19. 10.1007\/s12016-015-8510-y","journal-title":"Clin Rev Allergy Immunol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/89191-the-role-of-myositis-specific-autoantibodies-in-the-dermatomyositis-spectrum","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:41:50Z","timestamp":1707507710000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/89191-the-role-of-myositis-specific-autoantibodies-in-the-dermatomyositis-spectrum"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,8]]},"references-count":49,"URL":"https:\/\/doi.org\/10.7759\/cureus.22978","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2022,3,8]]}}}